Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Drugs

Every gastrointestinal stromal tumor program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.

ClassNone selected
Route

A route is listed here when at least one program uses it. The full list is on Methods. Unknown means the source did not name a route.

All programs shown

17 of 17 programs shown

anti-PD-L1 (with imatinib) 1 drug

  • Atezolizumab + ImatinibCentre Leon BerardPhase 2atezolizumab, intravenous. imatinib, oral1 studyanti-PD-L1 (with imatinib)

anti-PD-L1 (with regorafenib) 1 drug

  • Envafolimab + RegorafenibPeking UniversityPhase 2envafolimab, subcutaneous. regorafenib, oral1 studyanti-PD-L1 (with regorafenib)

Class not reported 1 drug

  • DCC-3009Deciphera PharmaceuticalsPhase 1/2oral1 studyClass not reported

HIF-2 alpha inhibitor 1 drug

HSP90 inhibitor (with imatinib) 1 drug

KIT type I TKI plus type II TKI combination 1 drug

KIT-directed ADC 1 drug

KIT/PDGFRA TKI (type II) 1 drug

KIT/PDGFRA type I TKI 1 drug

  • AvapritinibAyvakitBlueprint MedicinesApprovedoral2 studiesKIT/PDGFRA type I TKI

menin inhibitor (with imatinib) 1 drug

multi-kinase TKI 2 drugs

multi-kinase TKI (type II) 1 drug

selective KIT TKI 2 drugs

switch-control KIT/PDGFRA TKI 1 drug

  • RipretinibQinlockDeciphera PharmaceuticalsApprovedoral3 studiesswitch-control KIT/PDGFRA TKI

VEGFR2 TKI (with paclitaxel) 1 drug